Entrectinib Therapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Entrectinib Therapy, 2022, version number 1, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | v::ROS1 | Non-Small Cell Lung Cancer | Entrectinib |